Skip to Content

Hartford Healthcare R3 HGHRX

Medalist Rating as of | See Hartford Funds Investment Hub
  • NAV / 1-Day Return 39.90  /  +0.30 %
  • Total Assets 1.2 Bil
  • Adj. Expense Ratio
    1.610%
  • Expense Ratio 1.610%
  • Distribution Fee Level Above Average
  • Share Class Type Retirement, Medium
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment
  • Status Open
  • TTM Yield
  • Turnover 32%

USD | NAV as of Feb 23, 2024 | 1-Day Return as of Feb 23, 2024, 11:14 PM GMT+0

Morningstar’s Analysis HGHRX

Will HGHRX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A compelling, diversified healthcare option.

Analyst Andrew Redden

Andrew Redden

Analyst

Summary

A deep team and proven approach make Hartford Healthcare a worthwhile offering.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings HGHRX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 42.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

9.08 102.4 Mil
Healthcare

UnitedHealth Group Inc

7.80 88.0 Mil
Healthcare

Merck & Co Inc

5.86 66.2 Mil
Healthcare

Danaher Corp

3.84 43.4 Mil
Healthcare

Pfizer Inc

3.07 34.6 Mil
Healthcare

Boston Scientific Corp

2.64 29.7 Mil
Healthcare

Stryker Corp

2.62 29.5 Mil
Healthcare

Vertex Pharmaceuticals Inc

2.58 29.1 Mil
Healthcare

Zoetis Inc Class A

2.43 27.4 Mil
Healthcare

HCA Healthcare Inc

2.41 27.2 Mil
Healthcare